Maricel Apuli Sells 2,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $80.06, for a total value of $160,120.00. Following the transaction, the chief accounting officer owned 127,401 shares in the company, valued at approximately $10,199,724.06. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Price Performance

NASDAQ BBIO opened at $82.07 on Wednesday. BridgeBio Pharma, Inc. has a one year low of $42.09 and a one year high of $93.42. The firm has a market cap of $16.04 billion, a P/E ratio of -21.94 and a beta of 0.96. The stock’s 50-day moving average is $74.72 and its 200-day moving average is $72.83.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.51 million during the quarter, compared to analyst estimates of $178.07 million. The business’s revenue for the quarter was up 66.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.88) EPS. Equities analysts anticipate that BridgeBio Pharma, Inc. will post -2.27 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on BBIO shares. Morgan Stanley raised their price objective on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the stock an “overweight” rating in a report on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of BridgeBio Pharma in a research note on Friday, May 15th. Mizuho lowered their target price on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a report on Tuesday, June 16th. Canaccord Genuity Group began coverage on BridgeBio Pharma in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 price target on the stock. Finally, Royal Bank Of Canada began coverage on BridgeBio Pharma in a report on Thursday, April 9th. They issued an “outperform” rating and a $100.00 price target on the stock. Twenty equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.21.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds and other institutional investors have recently modified their holdings of BBIO. Harvest Fund Management Co. Ltd acquired a new stake in BridgeBio Pharma in the 3rd quarter valued at $34,000. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the first quarter worth $35,000. Farther Finance Advisors LLC lifted its stake in shares of BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after buying an additional 245 shares in the last quarter. Global Retirement Partners LLC lifted its stake in shares of BridgeBio Pharma by 271.5% in the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock valued at $39,000 after buying an additional 372 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of BridgeBio Pharma during the fourth quarter valued at about $41,000. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.